Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

First-in-Human Safety Study Of Laser Tissue Welding For Surtureless Laparoscopic Partial Nephrectomy (LTW-KIDNEY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02061605
Recruitment Status : Active, not recruiting
First Posted : February 13, 2014
Last Update Posted : March 1, 2019
Sponsor:
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
Laser Tissue Welding, Inc.

Brief Summary:
The objective of this pilot study will be to obtain a clinical safety and efficacy endpoint profile of laser tissue welding therapy for sealing the resected kidney surface after laparoscopic partial nephrectomy required for removal of resectable benign or malignant renal tumors in 10 patients.

Condition or disease Intervention/treatment Phase
Benign Renal Tumors Malignant Renal Tumors Device: Laser Tissue Welding Device Not Applicable

Detailed Description:

SCIENTIFIC RATIONALE:

The use of partial nephrectomy to treat small newly diagnosed kidney tumors is vastly under-used as per NCI statistics (http://www.cancer.gov/cancertopics/treatment/partial-nephrectomy0208).

As per the Surveillance, Epidemiology and End Results (SEER) Program, (http://seer.cancer.gov/statfacts/html/kidrp.html), the prevalence of cancer of the kidney and renal pelvis is 296,074 while the estimated new cases are 46,410 and deaths 13,040 in the United States in 2010 (www.cancer.gov/cancertopics/types/kidney).

There has been an increase in detection of incidental small renal mass (≤ 4cm) cases (TNM staging T1a) due to widespread use of ultrasound and abdominal cross sectional imaging (CT, MRI) and thus an increase in the amount of renal surgery performed. Current surgical practice for nephron sparing surgery allows at least 1 cm margin of normal tissue around the tumor3. This is the stage when curative resections are possible.

During a partial nephrectomy, the renal artery is clamped to minimize bleeding while resecting the tumor. Since a major reconstruction is required with suturing, clamp time can be significant, anywhere between 15 and 45 minutes. It has been repeatedly shown that reducing clamp time preserves renal function and that there is significant damage to the kidney if the renal artery is clamped for more than 30 minutes. This is especially crucial when dealing with patients with hypertension, diabetes, chronic renal failure or a tumor in a single kidney. Extended clamp time can result in decreased renal function and ultimately the need for dialysis at some point. Because of the inherent difficulties of laparoscopic suturing, this has not been widely used particularly in view of the risk of prolonged warm ischemia time. Many patients therefore undergo a radical nephrectomy instead of a nephron sparing procedure. Hemorrhage 9.5% (1) , is the major complication following partial nephrectomy. Besides bleeding (1) urinary fistula (4.5%), ureteral obstruction, and renal insufficiency due to prolonged warm ischemia times are further complications of partial nephrectomy.

Laser Tissue Welding is the first combination (laser and biologic) class III surgical device intended to join and seal tissues accurately and instantly. The treatment process uses thermal energy created when a laser excites photosensitive dye molecules, to coagulate the protein albumin which transforms from a liquid to a solid instantly. Laser tissue welding creates a non-compressive, non-ablative sealing of tissues with microscopic thermal damage. This combination of a laser with albumin biologics stops bleeding and fluid leaks in nanoseconds without using sutures, hemostatic clotting factors (platelets/thrombin/fibrin), thermal or cryoablation. (Video: http://www.lasertissuewelding.com/application.aspx?AID=8)


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase-I Feasibility Trial To Study The Safety Of Laser Tissue Welding For Sealing Resected Kidney Surfaces After Laparoscopic Partial Nephrectomy
Study Start Date : June 2016
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Cancer

Arm Intervention/treatment
Experimental: Laser Tissue Welding Device

The laser tissue welding device is intended for use in patients requiring laparoscopic surgery requiring hemostasis and sealing of the resected kidney after partial nephrectomy, and including those patients who are fully heparinized or have hemodilutional coagulation failure.

The device's intended use is to seal the kidney surface using a laser to weld human albumin based biomaterials after surgical removal of kidney tumors during a laparoscopic partial nephrectomy.

Device: Laser Tissue Welding Device
Laparoscopic partial nephrectomy will be robotically assisted using the second generation da Vinci® Surgical System. Once the tumor is resected with laparoscopic scissors with a margin of healthy tissue, the solder will be dripped onto the cut surface of the parenchyma. A laparoscopic rigid 5mm spot-size laser hand-piece will be passed through the 10-mm port. The diode laser will be then used to weld a thin layer of solder onto the cut parenchymal surface. The 60 Watt 810-nm diode laser will be set to deliver continuous energy. During soldering, the tip of the laparoscopic laser hand-piece will be maintained 1 to 2 cm from the renal surface to generate a spot size of approximately 5 mm. Each spot will be treated with the laser until the color of the solder changes from green to white. The renal pedicle clamp will be removed to allow renal blood supply to be restored and the surgical site inspected for evidence of bleeding for 10 minutes prior to completing the surgical procedure.




Primary Outcome Measures :
  1. Operative Blood Loss [ Time Frame: Day 1 ]

    Operative blood loss is defined by: Volume of blood in the suction bottles, volume of blood clots, and weight of surgical towels before and after use.

    Clinical assessment of the blood loss: Clinical drop in hemoglobin (1 gm. % = 300 ml) without hemo-dilution. Therefore is correlated with blood products transfused to compensate for the blood lost during surgery.


  2. Postoperative Blood Loss [ Time Frame: Up to 30 days ]

    Clinical assessment of the blood loss:

    1. Clinical drop in hemoglobin (1 gm. % = 300 ml) without hemodilution. Therefore is correlated with blood products transfused to compensate for the blood lost post-operatively.
    2. Correlated to post-operative JP tube drainage, amount and type.


Secondary Outcome Measures :
  1. Secondary hemorrhage or hematoma (safety issue no. 1) [ Time Frame: Up to 12 months ]
    Post-operative blood loss requiring return to the operating room

  2. Post-operative urinary leakage/ urinoma (safety issue no. 2) [ Time Frame: Up to 12 months ]
    Urinary leakage is measured in drainage bottles (ml/day) following surgery till a drain placed during the operation is removed before patient discharge. Accumulation of fluids around the kidney (blood or urine) will be assessed with U/S and CT scan at the mentioned time points.

  3. Secondary infection, intra‐abdominal abscess formation and septicemia (safety issue no. 3) [ Time Frame: Up to 12 months ]
    Surgical space abscess

  4. Urinary stone formation (safety issue no. 4) [ Time Frame: Up to 12 months ]
    To see if the protein solder is a nidus for stone formation


Other Outcome Measures:
  1. Total operating time (minutes) (Duration Metric -1) [ Time Frame: Day 1 ]
    Observed operative period

  2. Nephrectomy clamp time (minutes) (Duration Metric-2) [ Time Frame: Day 1 ]
    Observed intra-operatively. Assesses organ ischemia time and will correlate with compromised renal function post-surgery.

  3. Laser tissue welding time (sec/cm2) (Duration Metric-3) [ Time Frame: Day 1 ]

    Observed intra-operatively:

    Cumulative time to complete hemostasis. This will be compared to current standard of care time-to-hemostasis using suture closure which is anywhere between 15 and 45 minutes since a major renal reconstruction is required with suturing and therefore correlated to significant clamp time, renal ischemia and renal dysfunction.


  4. Length of ICU stay (Duration Metric-4) [ Time Frame: Up to 12 months ]
    Number of days spent in intensive care unit (ICU).

  5. Length hospital stay ((Duration Metric-5) [ Time Frame: Up to 12 months ]
    Total time spent as an in-patient



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. T1a (< 4 cm). All resectable benign, primary or secondary malignant tumors of one kidney. No bi‐lateral disease.
  2. Serum creatinine: ≤ 2.5 mg/dL
  3. Glomerular filtration rate greater than ≥ 50 ml/min/m2
  4. Platelet count ≥ 50,000/mm3
  5. Prothrombin time < 18 seconds
  6. Partial thromboplastin time (PTT) ≤ 1.5 times control
  7. Serum albumin levels > 3g/dL (Normal range 3.5 to 5 g/dL)

Exclusion Criteria:

  1. Age younger than 18 years old
  2. Severe uncorrected hypertension
  3. Uncorrectable coagulopathies
  4. Pregnancy
  5. Active urinary tract infection
  6. T1b (>4 cm) lesion and above
  7. Systemic or local infection
  8. Subject has known allergy or intolerance to iodine or human serum albumin
  9. Recent febrile illness that precludes or delays participation pre-operatively
  10. Treatment with another investigational drug or other intervention during the study and follow-up period.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02061605


Locations
Layout table for location information
United States, Texas
St. Luke's Episcopal Hospital
Houston, Texas, United States, 77030
Sponsors and Collaborators
Laser Tissue Welding, Inc.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Investigators
Layout table for investigator information
Principal Investigator: RICHARD LINK, M.D. Department of Urology, Baylor College of Medicine

Additional Information:
Layout table for additonal information
Responsible Party: Laser Tissue Welding, Inc.
ClinicalTrials.gov Identifier: NCT02061605     History of Changes
Other Study ID Numbers: LTW-LPN-01
R44DK094619-02 ( U.S. NIH Grant/Contract )
First Posted: February 13, 2014    Key Record Dates
Last Update Posted: March 1, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Laser Tissue Welding, Inc.:
Laparoscopic partial nephrectomy
Surgical hemostasis
Laser tissue welding
Tissue sealant

Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Neoplasms
Carcinoma, Renal Cell
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Kidney Diseases
Urologic Diseases
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type